氧化修饰高密度脂蛋白对培养人动脉平滑肌细胞细胞周期蛋白D_1基因表达的影响

动脉平滑肌细胞（ｓｍ ｏｏｔｈ ｍ ｕｓｃｌｅ ｃｅｌｌ,ＳＭＣ）是动脉粥样硬化（ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ,ＡＳ）斑块中的主要细胞,它的增殖在ＡＳ形成过程中极其重要．利用体外培养的人主动脉ＳＭＣ,观察了天然高密度脂蛋白（ｎａｔｉｖｅ ｈｉｇｈ ｄｅｎｓｉｔｙ ｌｉｐｏｐｒｏｔｅｉｎ,Ｎ－ＨＤＬ）及氧化修饰ＨＤＬ（ｏｘｉｄｉｚｅｄ ＨＤＬ,ＯＸ－ＨＤＬ）对培养人主动脉ＳＭＣ ｃｙｃｌｉｎ Ｄ１（细胞周期蛋白Ｄ１）基因转录表达的影响．结果表明：（１）Ｎ－ＨＤＬ对ＳＭＣｃｙｃｌｉｎ Ｄ１基因表达无影响（Ｐ＞ ０．０５）;（２）ＯＸ－ＨＤＬ使ＳＭＣｃｙｃｌｉｎ Ｄ１基因表达显著增强（Ｐ＜０．０１）,其表达量随时间（２、１２、２４ ｈ）延长而增加．上述结果表明,ＯＸ－ＨＤＬ的致ＡＳ作用可能与其刺激ＳＭＣｃｙｃｌｉｎ Ｄ１基因表达增加有关．     

r－干扰素对喉癌细胞系HEP－2HLA－DR抗原和增殖细胞核抗原表达的影响

本实验用人重组ｒ－干扰素（ｒｈｕ－ＩＦＮ）作用ＨＥＰ－２细胞后ＨＬＡ－ＤＲ抗原和增殖细胞核抗原（ＰＣＮＡ）表达的检测来探讨ｒ－干扰素对ＨＥＰ－２细胞ＨＬＡ－ＤＲ抗原表达诱导作用及体外抗增殖活性。用单克隆抗体ＣＲ３／４３（抗ＨＬＡ－ＤＲ）和Ｋｉ－６７（抗ＰＣＮＡ）。以链霉素一生物素技术（ＬＳＡＢ）检测ＨＥＰ－２细胞ＨＬＡ－ＤＲ抗原和ＰＣＮＡ表达,结果显示：ｒ－ＩＥＮ诱导ＨＬＡ－ＤＲ抗原和抑制ＰＣＮＡ表达其强弱与ｒ－ＩＦＮ剂量有关。资料提示：ｒ－ＩＦＮ不仅对ＨＥＰ－２细胞有细胞毒作用,同时能调节其细胞膜特性,因而在喉癌的治疗中是有效的。     

尿激酶抗人交联纤维蛋白—D—二聚体单抗化学偶合体的制备

利用双功能试剂Ｎ－琥珀酰亚胺－３（２－二硫吡啶）丙酸酯（ＳＰＤＰ）作交联剂,合成了尿激酶（ＵＫ）－抗人交联纤维蛋白降解物Ｄ－二聚体单抗（ＭＡ－ＨＩＤ１）化学偶合体（ＵＫ．ＭＡ－ＨＩＤ１）并用苯甲脒－Ｓｅｐｈａｒｏｓｅ６Ｂ及人交联纤维蛋白降解物Ｄ－二聚体－Ｓｅｐｈａｒｏｓｅ４Ｂ亲和柱纯化,获得偶合体产物,ＳＤＳ－ＰＡＧＥ呈现一条带,其分子量约为２０００００,纤维蛋白平板法测活结果显示,偶合体中酶比活     

实验性癫痫时海马内一氧化氮合酶的变化及其与谷氨酸受体的关系

应用免疫组织化学方法观察了青霉素致痫时海马内神经元型一氧化氮合酶（ｎＮＯＳ）表达的时程变化及海马内微量注射ＮＭＤＡ受体拮抗剂ＭＫ－８０１（５－ｍｅｔｈｙｌ－１０,１１－ｄｉｈｙｄｒｏ－５Ｈ－ｄｉｂｅｎｚｏ［ａ,ｄ］ｃｙｃｌｏｈｅｐｔａｎ－５,１０－ｉｍｉｎｅｍａｌｅａｔｅ）和非ＮＭＤＡ受体拮抗剂ＤＮＱＸ（６,７－ｄｉｎｉｔｒｏｑｕｉｎｏｘａｌｉｎｅ－２,３－ｄｉｏｎｅ）对大鼠海马内ｎＮＯＳ表达的影     

柱孢菌细胞色素P－450nor2cDNA克隆与表达

在真菌的反硝化作用中,一种独特的细胞色素Ｐ－４５０起着一氧化氮还原酶（Ｐ－４５０ｎｏｒ）的作用。用ｇｔｌｌ构建了柱孢菌（Ｃｙｌｉｎｄｒｏｃａｒｐｏｎｔｏｎｌｅｉｎｅｎｓｅ）ｃＤＮＡ文库。纯化的柱孢菌Ｃ。Ｐ－４５０ｎｏｒ２免疫兔,制备抗体。并用抗体筛选出阳性克隆。回收插入片段（Ｐ－４５０ｎｏｒ２ｃＤＮＡ）克隆到表达载体ｐＹＥＳ２中,并在酵母系统中表达。经Ｗｅｓｔｅｍ－ｂｌｏｔ分析验证,表达产物能与抗体反应产生特异性杂交带。酶分析结果表明：表达产物具有一氧化氮还原酶细胞包素Ｐ－４５０ｎｏｒ２的活性,能以ＮＡＤＨ或ＮＡＤＰＨ为供体,使ＮＯ还原先成Ｎ２Ｏ。     

大鼠延髓外周橄榄腹外侧核在中枢化学感受中的作用

本工作采用微量注射、电损毁、电刺激和微电泳的方法,探讨了大鼠延髓外周橄榄腹外侧核（ＬＶＰＯ）的否真正参与中枢化学感受功能。实验在３８只雄性ＳＤ大鼠上进行。结果表明：（１）微量注射酸化人工脑脊液于ＬＶＰＯ可引起隔神经放电活动明显加强。（２）微电泳给予Ｈ＾＋对ＬＶＰＯ的自发放电单位主要引起兴奋反应,微电泳给予Ｈ＾＋引起兴奋反应的部分单位也可被腹外侧表面微量注射酸化人工ＣＳＦ所兴奋。（３）损毁ＬＶＰＯ后     

铝对玉米生长和硝酸还原酶活性的影响

测定了生长在Ａｌ２（ＳＯ４）３１００μｍｏｌ／Ｌ氮素营养液中的两个玉米品种（ＳＣ７０４和ＶＡ３５的根系和叶片）的ＮＡＤＨ－硝酸还原酶（ＥＣ１．６．６．１）和ＮＡＤ（Ｐ）Ｈ－硝酸还原酶（ＥＣ１．６．６．２）活性。     

PARP酶抑制剂未引起整合的外源LacZ基因的丢失

使用聚ＡＤＰ核糖聚合酶（ＰＡＲＰ）ＮＡＤ位点抑制剂苯甲酰胺（ＢＡ）研究了降低ＰＡＲＰ酶活性对外源ＬａｃＺ基因整合稳定性的影响,利用ＤＮＡ体外重组技术将ＬａｃＺ基因全序列插入到真核表达载体载体ＰＳＶ２ｎｅｏ的ＨｉｎｄⅢ位点,构建了一个具有真核细胞ｎｅｏ基因筛选标记和ＬａｃＺ基因的真核表达重组体ＰＳＶ２ｎｅｏ－ｂｅｔａ－ｇａｌ将该重组体导入ＨｅＬａ细胞,经Ｇ４１８筛选获得了能稳定表达β－半乳糖苷酶的Ｈ     

NNK诱发BEP2D细胞产生活性氧及其对DNA的损伤

通过测定细胞内和细胞上清中活性氧（ｒｅａｃｔｉｖｅ ｏｘｙｇｅｎ ｓｐｅｃｉｅｓ,ＲＯＳ）水平,以及ＤＮＡ 加合物——８－羟基脱氧鸟嘌呤核苷（８－ｈｙｄｒｏｘｙｄｅｏｘｙｇｕａｎｏｓｉｎｅ,ＯＨ８ｄＧ）含量,对烟草特异亚硝胺类化合物４－甲基亚硝胺－１（３－吡啶基）－１－丁酮（４－（ｍ ｅｔｈｙｌｎｉｔｒｏｓａｍ ｉｎｏ）－１－（３－ｐｙｒｉｄｙｌ）－１－ｂｕｔａｎｏｎｅ,ＮＮＫ）诱发人乳头状病毒永生化的人支气管上皮细胞（ｈｕｍ ａｎ ｐａｐｉｌｌｏｍ ａｖｉｒｕｓ－ｉｍ ｍ ｏｒｔａｌｉｚｅｄ ｈｕｍ ａｎｂｒｏｎｃｈｉａｌｅｐｉｔｈｅｌｉａｌｃｅｌｌｌｉｎｅ,ＢＥＰ２Ｄ）产生的ＲＯＳ及其对ＤＮＡ 的氧化损伤进行研究,并观察纳米硒的保护作用．结果表明,ＢＥＰ２Ｄ 细胞经不同浓度的ＮＮＫ 作用后,细胞内和细胞上清中ＲＯＳ以及ＯＨ８ｄＧ含量均显著增加,并有较好的剂量效应关系．１ μｍ ｏｌ·Ｌ－ １纳米硒（ｎａｎｏｓｅｌｅｎｕｉｍ ,ＮＳ）能明显抑制ＮＮＫ 诱发ＢＥＰ２Ｄ细胞产生的ＲＯＳ及ＯＨ８ｄＧ 水平．揭示ＮＮＫ 能造成细胞的氧化损伤,而ＮＳ对ＮＮＫ 所致细胞的氧化损伤有保护作用．     

侧脑室注射一叶萩碱的心血管效应及作用机制

在麻醉大鼠侧脑室注射左旋一叶Ｑｉｕ碱（Ｌ－Ｓｅｃ）,记录动脉血压（ＡＰ）、心率（ＨＲ）及肾交感神经放电（ＲＳＮＤ）,观察前脑室周系统ＧＡＢＡ能紧张性活动改变引起的心血管效应。结果如下：（１）Ｌ－Ｓｅｃ可引起ＲＳＮＤ增加、ＡＰ升高和ＨＲ加快,并呈一定剂量－效应关系;但Ｌ－Ｓ盈余 于ｂｉｃｕｃｕｌｌｉｎｅ（Ｂｉｃ）。（２）Ｌ－Ｓｅｃ既能拮抗ｍｕｓｃｉｍｏｌ（Ｍｕｓ）,又能拮抗ｂａｃｌｏｆｅｎ（Ｂａｃ）     

Modulation of medical prefrontal cortical D1 receptors on the excitatory firing activity of nucleus accumbens neurons elicited by (-)-Stepholidine

(-)-Stepholidine (SPD), with D1 agonistic action, elicited an excitatory firing activity of nucleus accumbens (NAc) neurons by intravenous administration, but this effect was hardly observed by iontophoresis of SPD into the NAc. The present study intends to determine whether D1 receptors in the medial prefrontal cortex (mPFC) are involved in the action of SPD on the firing activity of NAc neurons in the chloral hydrate-anesthetized male rats. The results showed that the intra-mPFC microinjected SCH-23390 (D1 antagonist, 30 mM), but not the D2 antagonist spiperone (30 mM), significantly attenuated the enhanced firing activity induced by intravenous injection of SPD (2 mg/kg). Similarly, the excitatory firing of NAc neurons was also exhibited by the microinjection of either SPD or D1 agonist SKF-38393 into the mPFC. The SPD-induced excitatory effect was in a dose-dependent way from 277.8 +/- 51.3% (10 mM) to 1105.4 +/- 283.5% (30 mM) of NAc basal firing, which was completely reversed by SCH-23390 (i.v.). Furthermore, the direct D1 agonistic action of SPD on the mPFC neuron was observed with microiontophoresis. These results indicate that SPD possesses a direct agonistic action on the mPFC D1 receptors, by which it modulates the firing activity of NAc neurons.     

Modulation of a neuronal network by electrical high frequency stimulation in striatal slices of the rat in vitro

The effects of the GABA(A) receptor antagonist bicuculline, the D2-like receptor antagonist sulpiride and the D1-like receptor antagonist SCH-23390 on the electrical high frequency stimulation (HFS)-evoked gamma-aminobutyric acid (GABA) and dopamine (DA) release were measured from slices of the rat striatum by means of HPLC method with electrochemical detection. HFS with 130Hz stimulated veratridine-activated GABAergic neurons resulting in an increased GABA outflow while DA outflow decreased. In the presence of the GABA(A) receptor antagonist bicuculline extracellular GABA and DA outflow were enhanced. When the competitive dopamine D2-like receptor antagonist S-(-)-sulpiride was added to incubation medium, the HFS-evoked stimulatory effect on GABA outflow declined to values found after veratridine (1microM) without HFS. After co-incubation of sulpiride and the competitive D1-like receptor antagonist R-(+)-SCH-23390, the effect of sulpiride on HFS plus veratridine-evoked GABA outflow was completely reversed. Neither sulpiride nor SCH-23390 had any influence on the effect of HFS on veratridine-induced DA outflow. No effect of HFS on glutamate outflow was observed in all experiments. These results led us to suggest that in our model HFS primarily affects GABAergic neurons. These neurons are embedded in a neuronal network with a GABA-dopamine circuit, and thus, HFS interacts with a neuronal network, not only with one neurotransmitter system or one neuron population.     

The Selective Inhibition of the D1 Dopamine Receptor Results in an Increase of Metabolized Dopamine in the Rat Striatum

Our aim was to study the specific role of the postsynaptic D(1) receptors on dopaminergic response and analyze the metabolized dopamine (DA) in the rat striatum. We used male Wistar rats to evaluate the effects of different doses of a D(1) agonist (SKF-38393) and a D(1) antagonist (SCH-23390), and their co-administration. The levels of DA and L-3, 4-dihydroxyphenylacetic acid (DOPAC) were measured using high performance liquid chromatography. The systemic injection of SKF-38393 alone at 1, 5 and 10 mg/kg did not alter the DA and DOPAC levels or the DOPAC/DA ratio. In contrast, injection of SCH-23390 alone at 0.25, 0.5 and 1 mg/kg significantly increased the DA and DOPAC levels, as well as the DOPAC/DA ratio, compared with the respective control groups. The co-administration of SCH-23390+SKF-38393 did not alter the DA or DOPAC levels, but it did significantly inhibit the SCH-23390-induced increase of the DA and DOPAC levels. The SCH-23390+SKF-38393 and the SCH-23390-only groups showed an increase in the DOPAC/DA ratio. The co-administration of SCH-23390+PARGYLINE significantly decreased the DOPAC levels and the DOPAC/DA ratio compared with the control and SCH-23390 groups. Taken together, our results showed that selective inhibition with SCH-23390 produced an increase in metabolized DA via striatal monoamine oxidase. These findings also contribute to the understanding of the role of postsynaptic D(1) receptors in the long-loop negative feedback system in the rat striatum.     

Atypical neuroleptic properties ofl-stepholidine

Intravenous administration ofl-stepholidine (SPD), a dopamine (DA) receptor antagonist, increased the firing rate of DA neurons located in the ventral tegmental area (VTA) and substantia nigra pars compacta (SNC) in both anaesthetized and paralyzed rats. However, with the increase of dose, SPD selectively inhibited the firing activity of DA neurons in the VTA but not in the SNC. The inhibition was reversed by the DA agonist apomorphine (APO), suggesting that it may be via the mechanism of depolarization inactivation (DI). In rats, chronic adrninistration of SPD for 21 d dose-dependently decreased the number of spontaneously active DA neurons in the VTA, of which effect was reversed by APO (i. v.). In contrast, the same treatment failed to affect the population of DA neurons in the SNC. Similarly, the acute treatment of SPD also decreased the number of spontaneously firing DA neurons in the VTA, but not in the SNC. SPD per se only induced very weak catalepsy. Its catalepsy which was not in proportion to dosage was only observed in the dose range of 10–40 mg/kg and lasted 15 min. SPD effectively antagonized the APO (2 mg/kg, i. p.)-induced stereotypy.The above-mentioned results suggest that SPD selectively inactivates the DA neurons in the VTA not in the SNC. SPD may associate with a low incidence of extrapyramidal side-effects and may be ranked as a promising compound for searching for a new kind of atypical neuroleptics.     

（－）SPD和（－）THP对蓝斑核去甲肾上腺素能神经元自发放电的影响

利用在体记录大鼠蓝斑核神经元单位放电,研究了（－）ＳＰＤ和（－）ＴＨＰ对其放电活动的影响。结果表明：（－）ＳＰＤ通过去甲肾上腺素α２受体,以剂量依赖方式增强蓝斑核神经元放电,但较大剂量却对神经元放电有一定抑制。然而（－）ＴＨＰ可使蓝斑核去甲肾上腺素能神经元出现可逆性放电抑制。     

Atypical neuroleptic properties of l-stepholidine -Electrophysiological and behavioral studies

Intravenous administration of l-stepholidine (SPD), a dopamine (DA) receptor antagonist, in-creased the firing rate of DA neurons located in the ventral tegmental area (VTA) and substantia nigra pars compacta (SNC) in both anaesthetized and paralyzed rats. However, with the increase of dose, SPD selectively inhibited the fir-ing activity of DA neurons in the VTA but not in the SNC. The inhibition was reversed by the DA agonist apomor-phine (APO), suggesting that it may be via the mechanism of depolarization inactivation (DI). In rats, chronic admin-istration of SPD for 21 d dose-dependently decreased the number of spontaneously active DA neurons in the VTA, of which effect was reversed by APO (i. v. ). In contrast, the same treatment failed to affect the population of DA neu-rons in the SNC. Similarly, the acute treatment of SPD also decreased the number of spontaneously firing DA neurons in the VTA, but not in the SNC. SPD per se only induced very weak catalepsy. Its catalepsy which was not in pro-port     

Dopamine D(2) receptors mediate amylin's acute satiety effect

The anorectic effect of the pancreatic peptide amylin has been established in numerous studies. Here, we investigated the influence of a pretreatment with dopamine (DA) D(1)- and D(2)-receptor antagonists on the anorectic effect of intraperitoneally injected amylin in rats fed a medium-fat (18% fat) diet. In 24-h food-deprived rats, pretreatment with the DA D(2)-receptor antagonist raclopride [100 microg/kg (0.2 micromol/kg) ip] significantly attenuated amylin's (5 microg/kg ip) anorectic effect, whereas raclopride alone had no effect on food intake [i.e., food intakes 1 h after injection were (n = 12): NaCl/NaCl 7.3 +/- 0.5 g; NaCl/amylin 3.9 +/- 0.6; raclopride/NaCl 7.7 +/- 0.7; raclopride/amylin 5.6 +/- 0.7]. Pretreatment with another DA D(2) receptor antagonist, sulpiride [50 mg/kg (154 micromol/kg) ip], similarly reduced amylin's satiety effect, whereas pretreatment with the DA D(1)-receptor antagonist SCH-23390 [10 microg/kg (0.03 micromol/kg) ip] did not influence amylin's effect. SCH-23390, however, completely blocked the anorexia induced by D-amphetamine (0.3 mg/kg ip). These results suggest that, under the present feeding conditions, the dopaminergic system mediates part of amylin's inhibitory effect on feeding in rats when administered intraperitoneally. This seems to involve DA D(2) receptors but not D(1) receptors.     

Differential effects of intravenous R,S-(+/-)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its S(+)- and R(-)-enantiomers on dopamine transmission and extracellular signal regulated kinase phosphorylation (pERK) in the rat nucleus accumbens shell and core

R,S(+/-)-3,4-methylenedioxymethamphetamine (R,S(+/-)-MDMA, 'Ecstasy') is known to stimulate dopamine (DA) transmission in the nucleus accumbens (NAc). In order to investigate the post-synaptic correlates of pre-synaptic changes in DA transmission and their relationship with MDMA enantiomers, we studied the effects of R,S(+/-)-MDMA, S(+)-MDMA, and R(-)-MDMA on extracellular DA and phosphorylated extracellular signal regulated kinase (pERK) in the NAc shell and core. Male Sprague-Dawley rats, implanted with a catheter in the femoral vein and vertical concentric dialysis probes in the NAc shell and core, were administered i.v. saline, R,S(+/-)-MDMA, S(+)-MDMA, or R(-)-MDMA. Extracellular DA was monitored by in vivo microdialysis with HPLC. Intravenous R,S(+/-)-MDMA (0.64, 1, and 2 mg/kg) increased dialysate DA, preferentially in the shell, in a dose-related manner. S(+)-MDMA exerted similar effects but at lower doses than R,S(+/-)-MDMA, while R(-)-MDMA (1 and 2 mg/kg) failed to affect dialysate DA. R,S(+/-)- and S(+)-MDMA but not R(-)-MDMA increased ERK phosphorylation (expressed as density/neuron and number of pERK-positive neurons/area) in both subdivisions of the NAc. The administration of the D1 receptor antagonist, SCH 39166, prevented the increase in pERK elicited by R,S(+/-)-MDMA and S(+)-MDMA, while the D2/3 receptor antagonist, raclopride, increased pERK in the NAc core per se but failed to affect the R,S(+/-)-MDMA-elicited stimulation of pERK. The present results provide evidence that the DA stimulant effects of racemic MDMA are accounted for by the S(+)-enantiomer and that pERK may represent a post-synaptic correlate of the stimulant effect of R,S(+/-)-MDMA on D1-dependent DA transmission.     

D-2 dopamine antagonist-like effects of SCH 23390 on A9 and A10 dopamine neurons

The effects of SCH 23390 on d-amphetamine-induced suppression of A9 and A10 DA neuronal firing were determined. SCH 23390 potently reversed d-amphetamine on both A9 and A10 DA neurons. Compared to haloperidol, SCH 23390 was 5 times more potent on A9 DA neurons and 20 times more potent on A10 DA neurons. However, the magnitude of the reversal effect was greater with haloperidol than SCH 23390. In addition, haloperidol produced a further increase in firing of both A9 and A10 DA neurons after SCH 23390 maximally increased firing. It was concluded that SCH 23390 has D-2 DA antagonist-like properties, possibly mediated via an interaction at D-1 DA receptors, which may be functionally linked with D-2 DA receptors. The marked potency of SCH 23390 in reversing d-amphetamine could be due to its combined antagonist effects at 5HT2 and D-1 DA receptor sites.     

Dopamine induces inhibitory effects on the circular muscle contractility of mouse distal colon via D1- and D2-like receptors

Dopamine (DA) acts as gut motility modulator, via D1- and D2-like receptors, but its effective role is far from being clear. Since alterations of the dopaminergic system could lead to gastrointestinal dysfunctions, a characterization of the enteric dopaminergic system is mandatory. In this study, we investigated the role of DA and D1- and D2-like receptors in the contractility of the circular muscle of mouse distal colon by organ-bath technique. DA caused relaxation in carbachol-precontracted circular muscle strips, sensitive to domperidone, D2-like receptor antagonist, and mimicked by bromocriptine, D2-like receptor agonist. 7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH-23390), D1-like receptor antagonist, neural toxins, L-NAME (nitric oxide (NO) synthase inhibitor), 2′-deoxy-N₆-methyl adenosine 3′,5′-diphosphate diammonium salt (MRS 2179), purinergic P2Y1 antagonist, or adrenergic antagonists were ineffective. DA also reduced the amplitude of neurally evoked cholinergic contractions. The effect was mimicked by (±)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrobromide (SKF-38393), D1-like receptor agonist and antagonized by SCH-23390, MRS 2179, or L-NAME. Western blotting analysis determined the expression of DA receptor proteins in mouse distal colon. Notably, SCH-23390 per se induced an increase in amplitude of spontaneous and neurally evoked cholinergic contractions, unaffected by neural blockers, L-NAME, MRS 2179, muscarinic, adrenergic, or D2-like receptor antagonists. Indeed, SCH-23390-induced effects were antagonized by an adenylyl cyclase blocker. In conclusion, DA inhibits colonic motility in mice via D2- and D1-like receptors, the latter reducing acetylcholine release from enteric neurons, involving nitrergic and purinergic systems. Whether constitutively active D1-like receptors, linked to adenylyl cyclase pathway, are involved in a tonic inhibitory control of colonic contractility is questioned.